AspiSafe is developing a novel feeding tube to prevent aspiration, a common cause of ventilator associated pneumonia. A second product, a feeding tube bridle/holder, also prevents accidental removal of the tube by disoriented patients.
Bioharmony Therapeutics is developing a topical antibiotic to treat gram negative, multi-drug resistant A.baumannii in wounds and burns. The species is an opportunistic pathogen which is particularly threatening to hospitals and burn wards. It has been listed by the WHO as a priority target with a critical need for new therapeutics.
Concarlo Holdings is developing a therapeutic and companion diagnostic for ER+ HER2- breast cancer patients. The current standard of care is a new class of drugs called cdk4 inhibitors. Only ~50% of patients respond, and many develop resistance. Concarlo's diagnostic screens for cdk4 inhibitor therapy receptivity in the standard biopsy panel. Their therapeutic is an improved cdk4 inhibitor that blocks the pathway leading to resistance.
Digitouch Health is developing the first cuff-less oscillometric blood pressure diagnostic embedded in a smart phone case or bluetooth connected key fob.
ENB is developing a product to be used in combination with PD-1/PD-L1 immunotherapies. These immunotherapies are highly effective, but only in 15-20% of patients due to the lack of PD-1/PD-L1 expression by the tumor. ENB's lead product restores TIL (tumor infiltrating lymphocytes) infiltration into tumors, promoting expression of these receptors, and transforming the tumor to be receptive to PD-1/PD-L1 immunotherapies.
EpiVax Oncology is leveraging a proprietary computational platform, called Ancer, to design highly effective personalized cancer vaccines. A biopsy of a patient’s tumor is sequenced to elucidate specific mutations (called the mutanome). Ancer analyzes the mutanome to predict the most effective immuno-stimulatory epitopes.
Goldilocks is developing a drug delivery technology that specifically targets the kidney tubules. The first product is a therapeutic to prevent acute kidney injury from chemotherapy.
Marvel is developing a clinical diagnostic which enumerates genomic copy number variants (CNV) with unprecedented accuracy. CNV tests are currently used to diagnose congenital disorders and developmental conditions in children, including autism.
Mymee is a digital therapeutic company targeting chronic auto-immune disease. The platform combines an app for patient self reporting, a machine-learning analysis algorithm to extract causative and related triggers, and professional health tele-coaching to support the patient in modifying their behaviors.
PainQx is developing a diagnostic to quantify pain. It utilizes a standard EEG headset to perform a rapid reading that is processed by a proprietary, cloud-hosted algorithm. The company is targeting the clinical research and clinical markets.
Playback Health enables practitioners to create, store and share curated screen-captured video, audio and digital documents to inform and educate patients about their specific diagnosis, treatment and discharge.
Targagenix is developing a chemotherapy agent with significantly improved efficacy and reduced systemic toxicity. The compound is a nano-formulated, novel taxane designed to evade the common chemotherapy resistance pathways. The product is effective in numerous cancer types and has been shown to have synergy with PD-1/PD-L1 immunotherapy agents.
Frenzy is developing an AI brand-specific visual search tool for web-hosted images, targeting the affiliate sales market. The tool auto-tags the images with shoppable links, dramatically increasing sales conversion.
Co-founded by Vanguard Motorcycles, Eric Buell Racing, & Spark Racing Technologies, Vanguard Spark is designing stylish, high performance, competitively priced, electric motorcycles and bicycles for urban commuters.
StorEn Technologies is developing cost-competitive, small scale vanadium redox flow batteries for residential, small commercial and telecom applications.
Toggle is developing a Robotics as a Service (RaaS) platform to assemble rebar cages for reinforced concrete in construction applications. Their 2-arm robotic platform and proprietary jig design can build any shape directly from the computer blueprint (CAD or BIM file).
